SG11201908994RA - Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy - Google Patents
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapyInfo
- Publication number
- SG11201908994RA SG11201908994RA SG11201908994RA SG11201908994RA SG 11201908994R A SG11201908994R A SG 11201908994RA SG 11201908994R A SG11201908994R A SG 11201908994RA SG 11201908994R A SG11201908994R A SG 11201908994RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- tils
- october
- pct
- processes
- Prior art date
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 244000291564 Allium cepa Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 229940126587 biotherapeutics Drugs 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000010034 metabolic health Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT onion °nolo OH 1101 H mum° oimIE (10) International Publication Number WO 2018/182817 Al (51) International Patent Classification: C12N 5/0783 (2010.01) C12M 1/04 (2006.01) (21) International Application Number: PCT/US2018/012633 (22) International Filing Date: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/478,506 62/539,410 62/548,306 62/554,538 62/559,374 62/567,121 62/577,655 62/582,874 62/596,374 05 January 2018 (05.01.2018) English English Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 29 March 2017 (29.03.2017) US 31 July 2017 (31.07.2017) US 21 August 2017 (21.08.2017) US 05 September 2017 (05.09.2017) US 15 September 2017 (15.09.2017) US 02 October 2017 (02.10.2017) US 26 October 2017 (26.10.2017) US 07 November 2017 (07.11.2017) US 08 December 2017 (08.12.2017) US Applicant: IOVANCE BIOTHERAPEUTICS, INC. [US/US]; 999 Skyway Road, Suite 150, San Carlos, CA 94070 (US). Inventors; and Applicants: WARDELL, Seth [US/US]; 30204 USF Hol- ly Drive, Tampa, FL 33620 (US). BENDER, James [US/US]; 3 Cloverdale, Rancho Santa Margarita, CA 92688 (US). LOTZE, Michael, T. [US/US]; 5134 Westminster Place, Pittsburgh, PA 15232 (US). Agent: MACDOUGALL, Christina, A. et al.; Morgan, Lewis, & Bockius LLP, One Market, Spear Tower, San Fan- cisco, CA 94105 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, N GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, co co (54) Title: PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IM- MUNOTHERAPY 00 (57) : The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic O populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as C well as decreased costs. Such TILs fmd use in therapeutic treatment regimens.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478506P | 2017-03-29 | 2017-03-29 | |
US201762539410P | 2017-07-31 | 2017-07-31 | |
US201762548306P | 2017-08-21 | 2017-08-21 | |
US201762554538P | 2017-09-05 | 2017-09-05 | |
US201762559374P | 2017-09-15 | 2017-09-15 | |
US201762567121P | 2017-10-02 | 2017-10-02 | |
US201762577655P | 2017-10-26 | 2017-10-26 | |
US201762582874P | 2017-11-07 | 2017-11-07 | |
US201762596374P | 2017-12-08 | 2017-12-08 | |
PCT/US2018/012633 WO2018182817A1 (en) | 2017-03-29 | 2018-01-05 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908994RA true SG11201908994RA (en) | 2019-10-30 |
Family
ID=61569356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908994R SG11201908994RA (en) | 2017-03-29 | 2018-01-05 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
Country Status (33)
Country | Link |
---|---|
US (57) | US10894063B2 (en) |
EP (6) | EP3601533B1 (en) |
JP (5) | JP7169291B2 (en) |
KR (1) | KR20190142342A (en) |
CN (1) | CN110785486A (en) |
AU (1) | AU2018243355A1 (en) |
BR (1) | BR112019020326A2 (en) |
CA (1) | CA3057975A1 (en) |
CL (2) | CL2019002769A1 (en) |
CO (1) | CO2019011995A2 (en) |
CR (1) | CR20190487A (en) |
CY (1) | CY1124136T1 (en) |
DK (1) | DK3601533T3 (en) |
EC (1) | ECSP19077884A (en) |
ES (1) | ES2874335T3 (en) |
HR (1) | HRP20210677T1 (en) |
HU (1) | HUE054829T2 (en) |
IL (2) | IL305198A (en) |
JO (1) | JOP20190224A1 (en) |
LT (1) | LT3601533T (en) |
MD (1) | MD3601533T2 (en) |
MX (1) | MX2019011768A (en) |
NZ (1) | NZ758201A (en) |
PE (1) | PE20191841A1 (en) |
PH (1) | PH12019502247A1 (en) |
PL (1) | PL3601533T3 (en) |
PT (1) | PT3601533T (en) |
RS (1) | RS61863B1 (en) |
SG (1) | SG11201908994RA (en) |
SI (1) | SI3601533T1 (en) |
TN (1) | TN2019000273A1 (en) |
TW (1) | TWI799402B (en) |
WO (1) | WO2018182817A1 (en) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105163745B (en) | 2013-03-01 | 2020-06-12 | 美国卫生和人力服务部 | Method for generating enriched populations of tumor-reactive T cells from peripheral blood |
GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
SG11201903331QA (en) | 2016-10-26 | 2019-05-30 | Iovance Biotherapeutics Inc | Restimulation of cryopreserved tumor infiltrating lymphocytes |
US11332713B2 (en) | 2016-11-16 | 2022-05-17 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
BR112019018915A2 (en) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | targeted immunotolerance |
JOP20190224A1 (en) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
MX2019013517A (en) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Targeted immunotolerance. |
WO2018226714A1 (en) * | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
BR112020009663A2 (en) * | 2017-11-17 | 2020-11-10 | Iovance Biotherapeutics, Inc. | method for the expansion of tumor infiltrating lymphocytes (tils) in a therapeutic population of tils, method for the treatment of an individual with cancer, composition |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
BR112020018658A2 (en) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMU-NOTERAPY |
AU2019234926A1 (en) | 2018-03-15 | 2020-10-08 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
EA202092319A1 (en) * | 2018-03-29 | 2021-03-04 | Айовэнс Байотерапьютикс, Инк. | METHODS FOR OBTAINING TUMOR-INFILTING LYMPHOCYTES AND USING THEM IN IMMUNOTHERAPY |
KR20210005138A (en) | 2018-04-27 | 2021-01-13 | 이오반스 바이오테라퓨틱스, 인크. | Closure method for expansion and gene editing of tumor infiltrating lymphocytes and their use in immunotherapy |
WO2019217753A1 (en) * | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
MX2021004191A (en) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway. |
WO2020096989A1 (en) * | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
CN113272421A (en) | 2018-11-05 | 2021-08-17 | 艾欧凡斯生物治疗公司 | Method for generating tumor infiltrating lymphocytes and use thereof in immunotherapy |
MX2021004775A (en) | 2018-11-05 | 2021-06-08 | Iovance Biotherapeutics Inc | Expansion of tils utilizing akt pathway inhibitors. |
EP3877512A2 (en) * | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
JP2022506836A (en) * | 2018-11-08 | 2022-01-17 | ガンマデルタ セラピューティクス リミティッド | How to isolate and expand cells |
EP3898949A1 (en) * | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
CA3125762A1 (en) | 2019-01-10 | 2020-07-16 | Iovance Biotherapeutics, Inc. | System and methods for monitoring adoptive cell therapy clonality and persistence |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
JPWO2021006316A1 (en) * | 2019-07-10 | 2021-01-14 | ||
GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
JP2022544358A (en) * | 2019-08-12 | 2022-10-18 | ベリカム ファーマシューティカルズ, インコーポレイテッド | Improved formulations for immune cells |
JP2022546675A (en) | 2019-08-19 | 2022-11-07 | ウニベルシテート バーゼル | Methods of cell therapy |
WO2021061853A1 (en) * | 2019-09-24 | 2021-04-01 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
EP4048295A1 (en) * | 2019-10-25 | 2022-08-31 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
EP4069237A1 (en) | 2019-12-04 | 2022-10-12 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
CA3161104A1 (en) * | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
IL294098A (en) | 2019-12-20 | 2022-08-01 | Instil Bio Uk Ltd | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
JP7303391B2 (en) | 2020-01-14 | 2023-07-04 | シンセカイン インコーポレイテッド | Biased IL2 muteins, methods, and compositions |
JP2023524639A (en) * | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Manufacturing adjustment system and adjustment method of cells for patient-specific immunotherapy |
CA3176654A1 (en) | 2020-04-28 | 2021-11-04 | Karl PEGGS | T cell therapy |
CA3177413A1 (en) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
TW202208617A (en) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
JP2023527531A (en) * | 2020-05-29 | 2023-06-29 | シャンハイ ジュンセル セラピューティクス カンパニー リミテッド | Seed cell culture medium for tumor-infiltrating lymphocytes and use thereof |
CN111876381A (en) * | 2020-07-22 | 2020-11-03 | 中美冠科生物技术(太仓)有限公司 | T cell model and application thereof in-vitro human PD-1 antibody efficacy evaluation |
JP2023546359A (en) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
AU2021381496A1 (en) | 2020-11-23 | 2023-06-08 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
EP4253530A1 (en) | 2020-11-25 | 2023-10-04 | Shanghai Juncell Therapeutics Co., Ltd. | Tumor infiltration lymphocyte culture medium and application thereof |
EP4252754A1 (en) | 2020-11-25 | 2023-10-04 | Shanghai Juncell Therapeutics Co., Ltd. | Pharmaceutical composition for enhancing cell killing, and use thereof |
JP2024501452A (en) | 2020-12-11 | 2024-01-12 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer patients with tumor-infiltrating lymphocyte therapy in combination with BRAF inhibitors and/or MEK inhibitors |
JP2024500403A (en) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer with tumor-infiltrating lymphocytes |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
WO2022130015A2 (en) * | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
AU2021404204A1 (en) * | 2020-12-18 | 2023-07-06 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
EP4271791A2 (en) | 2020-12-31 | 2023-11-08 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
CN114686430A (en) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | Method for preparing TIL |
WO2022145490A1 (en) * | 2021-01-04 | 2022-07-07 | サイアス株式会社 | Method for producing regenerated t cell via ips cell |
TW202241508A (en) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
CA3172318A1 (en) | 2021-02-25 | 2022-09-01 | Suman Kumar VODNALA | Methods for culturing cells |
TW202300014A (en) | 2021-03-05 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Tumor storage and cell culture compositions |
EP4308691A1 (en) * | 2021-03-19 | 2024-01-24 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
JP2024512029A (en) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Methods and compositions for T cell co-culture efficacy assays and use with cell therapy products |
GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
WO2022214835A1 (en) | 2021-04-09 | 2022-10-13 | Achilles Therapeutics Uk Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
JP2024515189A (en) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy - Patents.com |
JP2024515815A (en) | 2021-04-27 | 2024-04-10 | 武田薬品工業株式会社 | Recombinant antigen-presenting cells |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
DE102021002748A1 (en) | 2021-05-27 | 2022-12-01 | Zellwerk Gmbh | Process for the production of tumor-infiltrated T-lymphocytes (TIL) and their use as cell therapeutics for the treatment of human tumors |
CA3223030A1 (en) * | 2021-06-17 | 2022-12-22 | CBio A/S | Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use |
KR20240023426A (en) | 2021-06-22 | 2024-02-21 | 아킬레스 테라퓨틱스 유케이 리미티드 | Method for producing antigen-specific T cells |
CA3226111A1 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
WO2023077034A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023137472A2 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
WO2023137471A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) * | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
GB202210006D0 (en) | 2022-07-07 | 2022-08-24 | Achilles Therapeutics Uk Ltd | Analysis of T cell samples |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
US20240093927A1 (en) * | 2022-09-16 | 2024-03-21 | Black & Decker, Inc. | Methods and devices for controlling the temperature of a surface |
WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
ES2382636T3 (en) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Method for producing compositions for improved administration of bioactive molecules |
CA2497552C (en) | 2002-09-06 | 2014-05-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
ITMI20022118A1 (en) | 2002-10-04 | 2004-04-05 | Abiogen Pharma Spa | PROCEDURE FOR THE LARGE SCALE CULTURE OF T-LYMPHOCYTES IN A HOMOGENEOUS SYSTEM. |
WO2005035728A2 (en) | 2003-10-08 | 2005-04-21 | Wilson Wolf Manufacturing Corporation | Cell culture methods and devices utilizing gas permeable materials |
CN109485727A (en) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
FR2911346B1 (en) * | 2007-01-12 | 2012-12-07 | Ct Hospitalier Universitaire De Nantes | PROCESS FOR IN VITRO CULTURE OF T CELLS, PARTICULARLY T CELLS INFILTANT TUMORS SAID TIL |
EP2203746B1 (en) * | 2007-09-24 | 2013-03-06 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
EP2510086A4 (en) | 2009-12-08 | 2013-05-22 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
CA3144697A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
WO2013057500A1 (en) * | 2011-10-21 | 2013-04-25 | Cell Medica Limited | Device for the aseptic expansion of cells |
GB201121308D0 (en) * | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
EP2850175B1 (en) | 2012-05-18 | 2020-12-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
WO2013188427A1 (en) | 2012-06-11 | 2013-12-19 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
CN105163745B (en) | 2013-03-01 | 2020-06-12 | 美国卫生和人力服务部 | Method for generating enriched populations of tumor-reactive T cells from peripheral blood |
US20160010058A1 (en) | 2013-03-01 | 2016-01-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of producing enriched populations of tumor-reactive t cells from tumor |
SG10201705494YA (en) | 2013-06-24 | 2017-08-30 | Wolf Wilson Mfg Corp | Closed system device and methods for gas permeable cell culture process |
EP3022294B1 (en) * | 2013-07-15 | 2019-11-20 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of preparing anti-human papillomavirus antigen t cells |
WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
KR20230085225A (en) | 2014-03-20 | 2023-06-13 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | Tumor-infiltrating lymphocytes for adoptive cell therapy |
US20170044496A1 (en) | 2014-04-10 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy |
EP3647412A1 (en) * | 2014-04-23 | 2020-05-06 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
WO2015189357A1 (en) | 2014-06-11 | 2015-12-17 | Polybiocept Ab | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
WO2015188839A2 (en) | 2014-06-13 | 2015-12-17 | Immudex Aps | General detection and isolation of specific cells by binding of labeled molecules |
JP6686008B2 (en) * | 2014-10-02 | 2020-04-22 | アメリカ合衆国 | Method for isolating T cell receptor having antigen specificity for cancer-specific mutation |
EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
FR3040396A1 (en) | 2015-06-30 | 2017-03-03 | Chu Nantes | PROCESS FOR CRYOPRESERVATION OF LYMPHOCYTES INFERATING THE TUMOR |
PE20191102A1 (en) | 2016-09-14 | 2019-08-23 | Abbvie Biotherapeutics Inc | ANTI-PD-1 ANTIBODIES AND THEIR USES |
SG11201903331QA (en) * | 2016-10-26 | 2019-05-30 | Iovance Biotherapeutics Inc | Restimulation of cryopreserved tumor infiltrating lymphocytes |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
TW201837168A (en) | 2017-01-06 | 2018-10-16 | 美商艾歐凡斯生物治療公司 | Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILS and TNFRSF agonists |
JOP20190224A1 (en) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
CN110832070A (en) | 2017-05-10 | 2020-02-21 | 艾欧凡斯生物治疗公司 | Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof |
WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
-
2017
- 2017-06-16 JO JOP/2019/0224A patent/JOP20190224A1/en unknown
-
2018
- 2018-01-05 BR BR112019020326A patent/BR112019020326A2/en unknown
- 2018-01-05 EP EP18709132.7A patent/EP3601533B1/en active Active
- 2018-01-05 MX MX2019011768A patent/MX2019011768A/en unknown
- 2018-01-05 RS RS20210622A patent/RS61863B1/en unknown
- 2018-01-05 EP EP23195819.0A patent/EP4279574A3/en active Pending
- 2018-01-05 HU HUE18709132A patent/HUE054829T2/en unknown
- 2018-01-05 TN TNP/2019/000273A patent/TN2019000273A1/en unknown
- 2018-01-05 DK DK18709132.7T patent/DK3601533T3/en active
- 2018-01-05 EP EP20161179.5A patent/EP3730608A1/en active Pending
- 2018-01-05 MD MDE20200116T patent/MD3601533T2/en unknown
- 2018-01-05 JP JP2019553050A patent/JP7169291B2/en active Active
- 2018-01-05 SI SI201830278T patent/SI3601533T1/en unknown
- 2018-01-05 NZ NZ758201A patent/NZ758201A/en unknown
- 2018-01-05 PL PL18709132T patent/PL3601533T3/en unknown
- 2018-01-05 EP EP21175134.2A patent/EP3910055A1/en active Pending
- 2018-01-05 KR KR1020197031407A patent/KR20190142342A/en not_active Application Discontinuation
- 2018-01-05 CR CR20190487A patent/CR20190487A/en unknown
- 2018-01-05 PE PE2019001976A patent/PE20191841A1/en unknown
- 2018-01-05 WO PCT/US2018/012633 patent/WO2018182817A1/en active Application Filing
- 2018-01-05 LT LTEP18709132.7T patent/LT3601533T/en unknown
- 2018-01-05 AU AU2018243355A patent/AU2018243355A1/en active Pending
- 2018-01-05 ES ES18709132T patent/ES2874335T3/en active Active
- 2018-01-05 CA CA3057975A patent/CA3057975A1/en active Pending
- 2018-01-05 TW TW107100568A patent/TWI799402B/en active
- 2018-01-05 PT PT187091327T patent/PT3601533T/en unknown
- 2018-01-05 CN CN201880035181.8A patent/CN110785486A/en active Pending
- 2018-01-05 US US15/863,634 patent/US10894063B2/en active Active
- 2018-01-05 IL IL305198A patent/IL305198A/en unknown
- 2018-01-05 EP EP20183493.4A patent/EP3766964A1/en active Pending
- 2018-01-05 SG SG11201908994R patent/SG11201908994RA/en unknown
- 2018-01-05 EP EP20161276.9A patent/EP3722415A1/en active Pending
- 2018-01-18 US US15/874,718 patent/US10166257B2/en active Active
- 2018-02-08 US US15/892,311 patent/US10130659B2/en active Active
- 2018-03-29 US US15/940,901 patent/US10918666B2/en active Active
- 2018-06-29 JP JP2020552291A patent/JP2021519582A/en active Pending
- 2018-06-29 US US17/041,305 patent/US20210079348A1/en active Pending
- 2018-09-19 US US16/136,147 patent/US10272113B2/en active Active
- 2018-09-19 US US16/136,157 patent/US10420799B2/en active Active
- 2018-11-15 US US16/192,707 patent/US10537595B2/en active Active
- 2018-11-27 US US16/201,957 patent/US10398734B2/en active Active
- 2018-11-28 US US16/203,467 patent/US10463697B2/en active Active
- 2018-11-28 US US16/203,478 patent/US10363273B2/en active Active
-
2019
- 2019-05-29 US US16/425,778 patent/US10646517B2/en active Active
- 2019-05-29 US US16/425,767 patent/US10695372B2/en active Active
- 2019-05-29 US US16/425,746 patent/US10639330B2/en active Active
- 2019-09-23 IL IL26954319A patent/IL269543A/en unknown
- 2019-09-27 PH PH12019502247A patent/PH12019502247A1/en unknown
- 2019-09-27 CL CL2019002769A patent/CL2019002769A1/en unknown
- 2019-10-28 CO CONC2019/0011995A patent/CO2019011995A2/en unknown
- 2019-10-29 EC ECSENADI201977884A patent/ECSP19077884A/en unknown
-
2020
- 2020-01-17 US US16/746,416 patent/US10653723B1/en active Active
- 2020-04-14 US US16/848,442 patent/US10933094B2/en active Active
- 2020-04-14 US US16/848,361 patent/US10905718B2/en active Active
- 2020-04-14 US US16/848,474 patent/US10946045B2/en active Active
- 2020-04-14 US US16/848,454 patent/US10946044B2/en active Active
- 2020-04-14 US US16/848,426 patent/US10953047B2/en active Active
- 2020-04-14 US US16/848,386 patent/US10953046B2/en active Active
- 2020-05-20 US US16/879,711 patent/US10925900B2/en active Active
- 2020-10-22 CL CL2020002737A patent/CL2020002737A1/en unknown
- 2020-12-02 US US17/110,207 patent/US11083752B2/en active Active
- 2020-12-02 US US17/110,179 patent/US20210100842A1/en active Pending
- 2020-12-18 US US17/127,840 patent/US11052116B2/en active Active
- 2020-12-18 US US17/127,795 patent/US11052115B2/en active Active
- 2020-12-18 US US17/127,790 patent/US11007226B2/en active Active
- 2020-12-18 US US17/127,768 patent/US11007225B1/en active Active
-
2021
- 2021-01-12 US US17/147,412 patent/US20210214685A1/en active Pending
- 2021-01-12 US US17/147,090 patent/US11040070B2/en active Active
- 2021-01-12 US US17/147,096 patent/US20210128625A1/en active Pending
- 2021-01-12 US US17/147,080 patent/US20210128623A1/en active Pending
- 2021-01-12 US US17/147,073 patent/US11013770B1/en active Active
- 2021-01-13 US US17/148,508 patent/US11168304B2/en active Active
- 2021-01-13 US US17/148,475 patent/US11168303B2/en active Active
- 2021-04-28 HR HRP20210677TT patent/HRP20210677T1/en unknown
- 2021-05-14 CY CY20211100416T patent/CY1124136T1/en unknown
- 2021-05-20 US US17/326,088 patent/US11202803B1/en active Active
- 2021-07-22 US US17/383,280 patent/US11304979B2/en active Active
- 2021-07-22 US US17/383,272 patent/US11202804B2/en active Active
- 2021-07-22 US US17/383,276 patent/US11273180B2/en active Active
- 2021-07-22 US US17/382,831 patent/US11241456B2/en active Active
- 2021-09-21 US US17/480,587 patent/US11344579B2/en active Active
- 2021-09-21 US US17/480,596 patent/US11337998B2/en active Active
- 2021-09-21 US US17/480,534 patent/US11291687B2/en active Active
- 2021-09-21 US US17/480,525 patent/US11273181B2/en active Active
-
2022
- 2022-07-01 US US17/856,806 patent/US20230133298A1/en active Pending
- 2022-07-01 US US17/856,793 patent/US20230015649A1/en active Pending
- 2022-07-01 US US17/856,800 patent/US11517592B1/en active Active
- 2022-08-03 US US17/817,247 patent/US20220387497A1/en active Pending
- 2022-08-03 US US17/817,207 patent/US20220387494A1/en active Pending
- 2022-08-03 US US17/817,279 patent/US11541077B2/en active Active
- 2022-08-03 US US17/817,281 patent/US11529372B1/en active Active
- 2022-08-03 US US17/817,217 patent/US20220395533A1/en active Pending
- 2022-08-03 US US17/817,232 patent/US20220387496A1/en active Granted
- 2022-08-03 US US17/817,239 patent/US20230012086A1/en active Pending
- 2022-08-03 US US17/817,273 patent/US20230045899A1/en active Pending
- 2022-08-03 US US17/817,226 patent/US20220387495A1/en active Pending
- 2022-08-03 US US17/817,276 patent/US20220387498A1/en active Pending
- 2022-10-28 JP JP2022173683A patent/JP2023012511A/en active Pending
- 2022-10-28 JP JP2022173684A patent/JP2023011778A/en active Pending
- 2022-10-28 JP JP2022173682A patent/JP2023012510A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908994RA (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
SG11201805217XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
SG11201804934PA (en) | Novel Compounds | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors |